Sale to NovaQuest Capital Management, LLC
Baird served as exclusive financial advisor to Clinical Ink, Inc. on this transaction
AboutClinical Ink, Inc. (“Clinical Ink” or the “Company”) was recently acquired by the private equity team at NovaQuest Capital Management, LLC (“NovaQuest”). RTI International, a leading research institute, provided strategic co-investment in support of Clinical Ink. Terms of the transaction were not disclosed.
Founded in 2007, Clinical Ink is dedicated to transforming clinical development with innovative technologies that make clinical research easier for patients, sites and sponsors. Clinical Ink’s SureSource® platform directly captures eSource, ePRO, and eCOA data and documents and facilitates risk-based monitoring. The Company’s approach puts the focus on protocol execution by focusing on the critical moments that matter. Clinical Ink maintains offices in Winston-Salem, North Carolina and Philadelphia, Pennsylvania.
NovaQuest is a leading investor in life sciences and healthcare, managing over $1.8bn, through its Product Finance and Private Equity strategies. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing and growing NovaQuest portfolio companies and investments. NovaQuest was founded in 2000 and is headquartered in Raleigh, North Carolina.
CONTACT US TO LEARN MORE
- May 2018
- Clinical Ink, Inc.
Technology & Services
- Target Location
- North America
- Acquiror Location
- North America
BGRS, a subsidiary of Relo, combination with SIRVA, a portfolio company of MDP
BHI, a portfolio company of AEI, acquisition by Westinghouse, a portfolio company of Brookfield